Relationship between vitamin D deficiency and bone fragility in sickle cell disease: A cohort study of 56 adults

Bone

Volumn 52, Issue 1, 2013, Pages 206-211

  Arlet, Jean Benoît ^a   Courbebaisse, Marie ^b   Chatellier, Gilles ^c   Eladari, Dominique ^b   Souberbielle, Jean Claude ^b   Friedlander, Gerard ^b   de Montalembert, Mariane ^b   Prié, Dominique ^b   Pouchot, Jacques ^a   Ribeil, Jean Antoine ^b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c INSERM   (France)

Author keywords

Bone mineral density; Fracture; Osteoporosis; Sickle cell disease; Vitamin D deficiency

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; PARATHYROID HORMONE;

ADOLESCENT; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; AVASCULAR NECROSIS; BONE DENSITY; BONE FRAGILITY; BONE METABOLISM; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MINERAL METABOLISM; OBSERVATIONAL STUDY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PREVALENCE; SECONDARY HYPERPARATHYROIDISM; SICKLE CELL ANEMIA; VERTEBRA MALFORMATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

ADULT; ANEMIA, SICKLE CELL; BONE AND BONES; COHORT STUDIES; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84867750908     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.10.005     Document Type: Article

References (28)

1. Fung E.B., Harmatz P.R., Milet M., Coates T.D., Thompson A.A., Ranalli M., et al. Multi-Center Iron Overload Study Group. Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone 2008, 43:162-168.
2. Almeida A., Roberts I. Bone involvement in sickle cell disease. Br J Haematol 2005, 129:482-490.
3. Miller R.G., Segal J.B., Ashar B.H., Leung S., Ahmed S., Siddique S., et al. High prevalence and correlates of low bone mineral density in young adults with sickle cell disease. Am J Hematol 2006, 81:236-241.
4. Adewoye A.H., Chen T.C., Ma Q., McMahon L., Mathieu J., Malabanan A., et al. Sickle cell bone disease: response to vitamin D and calcium. Am J Hematol 2008, 83:271-274.
5. Sadat-Ali M., Al-Elq A., Al-Turki H., Sultan O., Al-Ali A., AlMulhim F. Vitamin D level among patients with sickle cell anemia and its influence on bone mass. Am J Hematol 2011, 86:506-507.
6. Sarrai M., Duroseau H., D'Augustine J., Moktan S., Bellevue R. Bone mass density in adults with sickle cell disease. Br J Haematol 2007, 136:666-672.
7. Voskaridou E., Stoupa E., Antoniadou L., Premetis E., Konstantopoulos K., Papassotiriou I., et al. Osteoporosis and osteosclerosis in sickle cell/beta- thalassemia: the role of the RANKL/osteoprotegerin axis. Haematologica 2006, 91:813-816.
8. Gupta R., Marouf R., Adekile A. Pattern of bone mineral density in sickle cell disease patients with the high-Hb F phenotype. Acta Haematol 2010, 123:64-70.
9. Baldanzi G., Traina F., Marques Neto J.F., Santos A.O., Ramos C.D., Saad S.T. Low bone mass density is associated with hemolysis in brazilian patients with sickle cell disease. Clinics (Sao Paulo) 2011, 66:801-805.
10. Reynolds J. A re-evaluation of the "fish vertebra" sign in sickle cell hemoglobinopathy. Am J Roentgenol Radium Ther Nucl Med 1966, 97:693-707.
11. Goodman B.M., Artz N., Radford B., Chen I.A. Prevalence of vitamin D deficiency in adults with sickle cell disease. J Natl Med Assoc 2010, 102:332-335.
12. Buison A.M., Kawchak D.A., Schall J., Ohene-Frempong K., Stallings V.A., Zemel B.S. Low vitamin D status in children with sickle cell disease. J Pediatr 2004, 145:622-627.
13. Rovner A.J., Stallings V.A., Kawchak D.A., Schall J.I., Ohene-Frempong K., Zemel B.S. High risk of vitamin D deficiency in children with sickle cell disease. J Am Diet Assoc 2008, 108:1512-1516.
14. Chapelon E., Garabedian M., Brousse V., Souberbielle J.C., Bresson J.L., de Montalembert M. Osteopenia and vitamin D deficiency in children with sickle cell disease. Eur J Haematol 2009, 83:572-578.
15. Osunkwo I., Hodgman E.I., Cherry K., Dampier C., Eckman J., Ziegler T.R., et al. Vitamin D deficiency and chronic pain in sickle cell disease. Br J Haematol 2011, 153:538-540.
16. Rosen C.J. Clinical practice. Vitamin D insufficiency. N Engl J Med 2011, 364:248-254.
17. Holick M.F. Vitamin D, deficiency. N Engl J Med 2007, 357:266-281.
18. Conference development consensus: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993, 94:646-650.
19. Souberbielle J.C., Lawson-Body E., Hammadi B., Sarfati E., Kahan A., Cormier C. The use in clinical practice of parathyroid hormone normative values established in vitamin D-sufficient subjects. J Clin Endocrinol Metab 2003, 88:3501-3504.
20. Ebong W.W. Pathological fracture complicating long bone osteomyelitis in patients with sickle cell disease. J Pediatr Orthop 1986, 6:177-181.
21. Lal A., Fung E.B., Pakbaz Z., Hackney-Stephens E., Vichinsky E.P. Bone mineral density in children with sickle cell anemia. Pediatr Blood Cancer 2006, 47:901-906.
22. Smith W.R., Penberthy L.T., Bovbjerg V.E., McClish D.K., Roberts J.D., Dahman B., et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med 2008, 148:94-101.
23. Napoli N., Carmina E., Bucchieri S., Sferrazza C., Rini G.B., Di Fede G. Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. Bone 2006, 38:888-892.
24. Compston J.E., Thompson R.P.H. Intestinal absorption of 25-hydroxyvitamin D and osteomalacia in primary biliary cirrhosis. Lancet 1977, 1:721-724.
25. Ebert E.C., Nagar M., Hagspiel K.D. Gastrointestinal and hepatic complications of sickle cell disease. Clin Gastroenterol Hepatol 2010, 8:483-489.
26. Parikh S.J., Edelman M., Uwaifo G.I., Freedman R.J., Semega-Janneh M., Reynolds J., et al. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab 2004, 89:1196-1199.
27. Voskaridou E., Christoulas D., Konstantinidou M., Tsiftsakis E., Alexakos P., Terpos E. Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica 2008, 93:1588-1590.
28. Terpos E., Voskaridou E. Treatment options for thalassemia patients with osteoporosis. Ann N Y Acad Sci 2010, 1202:237-243.